natgillin/translations-raw huggingface dataset:
I gruppen med E/C/F/TAF var de mutationer, der opstod, M184V/I (n = 9) og K65R/N (n = 2) i RT og T66T/A/I/V (n = 2), E92Q (n = 4), Q148Q/R (n = 1) og N155H (n = 2) i integrase.
In the E/C/F/TAF group, the mutations that emerged were M184V/I (n = 9) and K65R/N (n = 2) in RT and T66T/A/I/V (n = 2), E92Q (n = 4), Q148Q/R (n = 1), and N155H (n = 2) in integrase.
I gruppen med grad 3 eller 4 leverrelateret laboratorietoksicitet var andelen, som samtidig havde hepatitis B henholdsvis hepatitis C-virus, 6,7 % og 20,0% i ”nevirapin 2 gange daglig”gruppen, og 5,6 % og 11,1% i efavirenzgruppen.
Of the patients with grade 3 or 4 liver-associated laboratory toxicity, the proportions coinfected with hepatitis B or hepatitis C virus were 6.7 % and 20.0 % in the nevirapine twice daily group, 5.6 % and 11.1 % in the efavirenz group.
I gruppen med lenalidomid/lavdosis dexamethason gennemgik 20 patienter (9,1 %) mindst én dosisafbrydelse, sammenlignet med 65 patienter (29,3 %) i armen med lenalidomid/standarddosis dexamethason.
In the lenalidomide/low dose dexamethasone group, 20 patients (9.1%) underwent at least one dose interruption compared to 65 patients (29.3%) in the lenalidomide/standard dose dexamethasone arm.
I gruppen, der fik atazanavir 300 mg administreret sammen med ritonavir 100 mg, forelå der evaluerbare genotypiske data for alle 12 virologiske svigt (3%, 12/348) og ingen af forsøgspersonerne havde behandlingsfremkaldt resistens over for nogen af indholdsstofferne i behandlingen.
In the group receiving atazanavir 300 mg co-administered with ritonavir 100 mg, evaluable genotypic data was available for all 12 virologic failures (3%, 12/348) and no subject had emergent resistance to any component of the regimen.
I grupperne med palonosetron 10 mcg/kg, 20 mcg/kg og ondansetron var andelen af patienter med CR0- 24t henholdsvis 54,2 %, 59,4 % og 58,6 %.
In the palonosetron 10 mcg/kg, 20 mcg/kg and ondansetron groups, the proportion of patients with CR0-24h was 54.2%, 59.4% and 58.6%.
I grupperne med tipranavir og komparator var median baseline CD4 celletal hhv.
In the tipranavir and comparator arms median baseline CD4 cell counts were 158 and 166 cells/mm3, respectively, (ranges 1-1893 and 1
I GS-US-216-130 forelå baseline-fænotype ikke
In GS-US216-130 baseline phenotype was not available
I HD- Dex-armen blev dexamethason (40 mg) administreret én gang dagligt på dag 1-4, 9-12 og 17-20 i en 28-dags cyklus.
For the HD-Dex arm, dexamethasone (40 mg) was administered once per day on Days 1 through 4, 9 through 12, and 17 through 20 of a 28-day cycle.
I HD-Dex-armen var den mediane PFS-tid 8,0 uger (95 % CI: 7,0-9,0), og den estimerede 26-ugers hændelsesfrie overlevelsesrate var 12,15 %
In the HD-Dex arm, median PFS time was 8.0 weeks (95% CI: 7.0, 9.0); the estimated 26-week event-free survival rate was 12.15% (±3.63%).
I hele behandlingsperioden vil lægen omhyggeligt kontrollere Dem og vælge den mest passende Yondelis- dosis til Dem.
During the treatment period, your doctor will carefully monitor you and decide the most appropriate dosage of Yondelis to give to you.
I henhold til ALARA-princippet (”As Low As Reasonably Achievable”) anbefales det imidlertid for at minimere strålingseksponeringen at minimere den tid, der tilbringes i strålingsområder,,maksimere afstanden til strålekilder, samt at anvende tilstrækkelig afskærmning.
However, in keeping with the ALARA (“As Low As Reasonably Achievable”) principle, for minimisation of radiation exposure, it is recommended to minimise the time spent in radiation areas, to maximise the distance to radiation sources, and to use adequate shielding.
I henhold til artikel 114 i direktiv 2001/83/EC foretages den officielle batchfrigivelse af et statsligt laboratorium eller et laboratorium udpeget hertil.
In accordance with Article 114 of Directive 2001/83/EC, the official batch release will be taken by a state laboratory or a laboratory designated for that purpose
I henhold til artikel 114 i direktiv 2001/83/EC foretages den officielle batchfrigivelse af et statsligt laboratorium eller et laboratorium udpeget hertil.‌
In accordance with Article 114 of Directive 2001/83/EC as amended, the official batch release will be undertaken by a state laboratory or a laboratory designated for that purpose.‌
I henhold til artikel 71 i Rådets direktiv 2001/82/EC kan en medlemsstat forbyde indførsel, salg, levering og/eller anvendelse af det veterinære lægemiddel på hele eller en del af sit område, hvis det godtgøres:
According to Article 71 of Directive 2001/82/EC as amended, Member States prohibit or may prohibit the import, sale, supply and/or use of the veterinary medicinal product on the whole or part of their territory if it is established that:
I henhold til center var hazard ratio med rivaroxaban i forhold til warfarin i den højeste tertil (0,642 (95% KI: 0,277-1,484).
Within the highest tertile according to centre, the hazard ratio with rivaroxaban versus warfarin was 0.642 (95% CI: 0.277 - 1.484).
I henhold til center var hazard ratio med rivaroxaban i forhold til warfarin i den højeste tertil 0,69 (95 % KI: 0,35-1,35).
Within the highest tertile according to centre, the hazard ratio with rivaroxaban versus warfarin was 0.69 (95% CI: 0.35 - 1.35).
I henhold til CHMP's Retningslinjer for risikostyringssystemer for medicinske produkter til human brug skal den opdaterede risikostyringsplan indsendes samtidig med den næste Periodiske sikkerhedsopdateringsrapport (PSUR).
As per the CHMP Guideline on Risk Management Systems for medicinal products for human use, the updated RMP should be submitted at the same time as the next Periodic Safety Update Report (PSUR).
I henhold til CHMPs ”Guideline on Risk Management Systems for medicinal products for human use”, bør den opdaterede RMP indsendes samtidig som den næste Periodic Safety Update Report (PSUR).
As per the CHMP Guideline on Risk Management Systems for medicinal products for human use, the updated RMP should be submitted at the same time as the next Periodic Safety Update Report (PSUR).
I henhold til den ændrede artikel 114 i direktiv 2001/83/EF foretages den officielle batchfrigivelse af et statsligt laboratorium eller et laboratorium udpeget hertil.
In accordance with Article 114 of Directive 2001/83/EC as amended, the official batch release will be undertaken by a state laboratory or a laboratory designated for that purpose
I henhold til denne daglige carbidopa- dosis, er den anbefalede daglige maksimale dosis for styrken 175 mg/43,75 mg/200 mg 8 tabletter pr. dag og for 200 mg/50 mg/200 mg 7 tabletter pr. dag.
According to this daily carbidopa dose, the maximum recommended daily 175 mg/43.75 mg/200 mg dose is 8 tablets per day and Corbilta 200 mg/50 mg/200 mg dose is 7 tablets per day.
I henhold til denne daglige carbidopa- dosis, er den anbefalede daglige maksimale dosis for styrken 175 mg/43,75 mg/200 mg 8 tabletter pr. dag og for 200 mg/50 mg/200 mg 7 tabletter pr. dag.
According to this daily carbidopa dose, the maximum recommended daily Corbilta 175 mg/43.75 mg/200 mg dose is 8 tablets per day and Corbilta 200 mg/50 mg/200 mg dose is 7 tablets per day.
I henhold til denne daglige carbidopa- dosis, er den anbefalede daglige maksimale dosis for styrken 175 mg/43,75 mg/200 mg 8 tabletter pr. dag og for 200 mg/50 mg/200 mg 7 tabletter pr. dag.
According to this daily carbidopa dose, the maximum recommended daily Levodopa/Carbidopa/Entacapone Orion 175 mg/43.75 mg/200 mg dose is 8 tablets per day and Levodopa/Carbidopa/Entacapone Orion 200 mg/50 mg/200 mg dose is 7 tablets per day.
I henhold til denne daglige carbidopa- dosis, er den anbefalede daglige maksimale dosis for styrken 175 mg/43,75 mg/200 mg 8 tabletter pr. dag og for 200 mg/50 mg/200 mg 7 tabletter pr. dag.
According to this daily carbidopa dose, the maximum recommended daily Stalevo 175 mg/43.75 mg/200 mg dose is 8 tablets per day and Stalevo 200 mg/50 mg/200 mg dose is 7 tablets per day.
I henhold til denne daglige carbidopa- dosis, er den anbefalede daglige maksimale dosis for styrken 175 mg/43,75 mg/200 mg 8 tabletter pr. dag og for200 mg/50 mg/200 mg 7 tabletter pr. dag.
According to this daily carbidopa dose, the maximum recommended daily Stalevo 175 mg/43.75 mg/200 mg dose is 8 tablets per day and Stalevo 200 mg/50 mg/200 mg dose is 7 tablets per day.
I henhold til denne daglige carbidopa- dosis, er den anbefalede daglige maximale dosis for styrken 175 mg/43,75 mg/200 mg 8 tabletter pr. dag og for 200 mg/50 mg/200 mg 7 tabletter pr. dag.
According to this daily carbidopa dose, the maximum recommended daily Stalevo 175 mg/43.75 mg/200 mg dose is 8 tablets per day and Stalevo 200 mg/50 mg/200 mg dose is 7 tablets per day.
I henhold til et farmakokinetisk studie med indgivelse af en enkelt dosis til raske frivillige bliver sevelamerhydrochlorid ikke absorberet fra mave-tarm-kanalen.
Sevelamer hydrochloride is not absorbed from the gastrointestinal tract according to a single dose pharmacokinetic study in healthy volunteers.
I henhold til gældende behandlingsvejledninger anbefales samtidig behanding med to proteasehæmmere generelt ikke.
According to current treatment guidelines, dual therapy with protease inhibitors is generally not recommended.
I henhold til gældende behandlingsvejledninger anbefales samtidig behandling med to proteasehæmmere generelt ikke.
According to current treatment guidelines, dual therapy with protease inhibitors is generally not recommended.
I henhold til gældende opfattelse er symptomer ved Parkinsons sygdom knyttet til manglen på dopamin i corpus striatum.
According to the current understanding, the symptoms of Parkinson’s disease are related to depletion of dopamine in the corpus striatum.
I henhold til kriterierne fra Memorial Sloan Kettering Cancer Center (MSKCC) for prognostisk risiko-kategori var 46 % i risikogruppen gunstig (0 risikofaktorer), 42 % var i risikogruppen middel (1 risikofaktor), og 13 % var i risikogruppen ringe (2 eller 3 risikofaktorer).
According to the Memorial Sloan Kettering Cancer Center criteria for prognostic risk category, 46% were favorable (0 risk factors), 42% were intermediate (1 risk factor), and 13% were poor (2 or 3 risk factors).
I henhold til LOCF (last obervation carried forward)
a Imputations according to the TLOVR algorithm b Last Observation Carried Forward imputation
I henhold til LOCF (last observation carried forward).
Last Observation Carried Forward imputation
I henhold til MedDRA
MedDRA preferred Term
I henhold til studiedesign kan patienterne i langtids- opfølgningsperioden have skiftet mellem doserne 50 mg og 100 mg Simponi efter studielægens skøn.
By study design, patients in the long-term extension may have switched between the 50 mg and 100 mg Simponi doses at the discretion of the study physician.
I henhold til studiedesign kan patienterne i langtids-opfølgningsperioden have skiftet mellem doserne 50 mg og 100 mg Simponi efter studielægens skøn.
By study design, patients in the long-term extension may have switched bewtween the 50 mg and 100 mg Simponi doses at the discretion of the study physician.
I henhold til studiedesignet kan patienterne i langtidsopfølgningen af de enkelte RA-studier have skiftet mellem doserne 50 mg og 100 mg Simponi efter studielægens skøn.
In each of the RA studies by study design, patients in the long-term extension may have switched between the 50 mg and 100 mg Simponi doses at the discretion of the study physician.
I henhold til studier på rotter om massebalance, vævsdistribution og helkrops- autoradioluminografi fordeles peginterferon alfa-2a, udover at opkoncentreres i blodet, til lever, nyrer og knoglemarv.
From mass balance, tissue distribution and whole body autoradioluminography studies performed in rats, peginterferon alfa-2a is distributed to the liver, kidney and bone marrow in addition to being highly concentrated in the blood.
I henhold til TLOVR-algoritmen
Imputations according to the TLOVR algorithm
I henhold til TLOVR-algoritmen (time to loss of viral response)
Imputations according to the TLOVR algorithm
I henhold til TLOVR-algoritmen (time to loss of viral response).
Imputations according to the TLOVR algorithm
I henhold til TLOVR-algoritmen (time to loss of viral response).
Imputations according to the TLOVR algorithm.
I henhold til TLOVR-algoritmen (time to loss of vrtal response)
Imputations according to the TLOVR algorithm
I henhold til ”CHMP Guideline on Risk Management Systems for Medicinal Products for Human Use” skal den opdaterede RMP indsendes samtidig med den næste periodiske sikkerhedsopdate- ringsrapport (PSUR).
As per the CHMP Guideline on Risk Management Systems for medicinal products for human use, the updated RMP should be submitted at the same time as the next Periodic Safety Update Report (PSUR).
I hiv 1-isolaterne fra 8 patienter med resistensudvikling i E/C/F/TDF-gruppen var de mutationer, der opstod, M184V/I (n = 6) og K65R/N (n = 3) i RT og E92E/Q (n = 2) og Q148R (n = 2) og N155H/S (n = 2) i integrase.
Of the HIV-1 isolates from 8 patients with resistance development in the E/C/F/TDF group, the mutations that emerged were M184V/I (n = 6) and K65R/N (n = 3) in RT and E92E/Q (n = 2), and Q148R (n = 2), and N155H/S (n = 2) in integrase.
I hiv-inficerede pædiatriske patienter var indinavirs farmakokinetiske parametre i æblemos: AUC0-8 timer på 26980 nM*t; maksimal plasmakoncentration på 13711 nM og plasmakoncentration på 146 nM 8 timer efter dosering.
In HIV–infected paediatric patients, the pharmacokinetic parameters of indinavir in apple sauce were: AUC0–8hr of 26,980 nM*h; peak plasma concentration of 13,711 nM; and plasma concentration at 8 hours post dose of 146 nM.
I hiv-inficerede pædiatriske patienter, gav et dosisregimen af indinavir hårde kapsler, 500 mg/m2 hver
In HIVinfected paediatric patients, a dose regimen of indinavir hard capsules, 500 mg/m2 every
i hjernen eller rygsøjlen
in your brain or in your spinal column
i hjernen i maven, lungerne eller i den hinde, der omgiver hjertet
in your brain in your abdomen, lungs or in the membrane surrounding the heart
I hjernen nedsætter GABA den elektriske aktivitet.
In the brain GABA is involved in reducing the electrical activity.
I hjernen stimulerer det receptorerne for GABA, et stof der er med til at reducere hjernens elektriske aktivitet.
In the brain it stimulates receptors for GABA, a substance involved in reducing electrical activity in the brain.
I hjernen.
In your brain
I HORIZONS-studiet blev trombocytopeni rapporteret hos 26 (1,6 %) af de bivalirudinbehandlede patienter og hos 67 (3,9 %) af de patienter, som blev behandlet med heparin plus en GP IIb/IIIa- inhibitor.
In the HORIZONS study, thrombocytopenia was reported in 26 (1. 6%) of bivalirudin-treated patients and in 67 (3.9%) of patients treated with heparin plus a GP IIb/IIIa inhibitor.
I hovedfeltundersøgelsen blev hunde af forskellige racer, aldersgrupper, køn og vægt behandlet med enten Certifect eller et tilsvarende spot-on-lægemiddel med fipronil og (S)-methopren.
In the main field study, dogs of various breeds, age groups, gender and different weights were treated with either Certifect or a similar ‘spot-on’ medicine containing fipronil and (S)-methoprene.
I hovedfeltundersøgelsen blev hunde og katte af forskellige racer, aldersgrupper, køn og vægtklasser enten behandlet med Activyl eller fipronil, et andet spot-on- lægemiddel, som er godkendt til denne indikation i Den Europæiske Union.
In the main field study, dogs and cats of various breeds, age groups, gender and different weights were treated either with Activyl or fipronil, another spot-on medicine which is authorised in the European Union for this indication.
I hovedparten af disse undersøgelser blev Taxotere kombineret med andre kræftmidler, og det blev sammenlignet med andre lægemiddelkombinationer eller med samme behandling uden Taxotere.
In most of these studies, Taxotere was combined with other anticancer treatments and compared either with combinations of different treatments or with the same treatments but without Taxotere.
I hovedundersøgelsen blev virkningen af Advate til behandling af blødning bedømt som ”særdeles god” eller ”god” i 86 % af de 510 nye blødningsepisoder.
In the main study, the effectiveness of Advate in the treatment of bleeding was rated as ‘excellent’ or ‘good’ in 86% of 510 new bleeding episodes.
I hovedundersøgelsen fik 49 % (21 ud af 43) af de voksne patienter, der fik Soliris, stabiliseret deres hæmoglobinprocent, og de behøvede i det store hele ikke transfusion af røde blodlegemer.
In the main study in PNH, 49% of the adult patients receiving Soliris had stable haemoglobin levels (21 out of 43), and, on average, they did not need any transfusions of red blood cells.
I hovedundersøgelsen forlængede Jevtana den samlede overlevelse i forhold til sammenligningslægemidlet mitoxantron.
In the main study, Jevtana prolonged overall survival compared with the comparator medicine mitoxantrone.
I hovedundersøgelsen havde patienter, som fik Nivestim, svær neutropeni i en tilsvarende tidsperiode som patienter, der fik Neupogen.
In the main study, the patients who received Nivestim had severe neutropenia for a similar length of time as the patients who received Neupogen.
I hovedundersøgelsen var det lige så effektivt at skifte til Atripla som at fortsætte med den tidligere behandlingskombination.
In the main study, switching to Atripla was as effective as remaining on the previous treatment combination.
I hovedundersøgelsen viste Pravafenix sig at være mere effektivt end pravastatin alene til reduktion af ikke-HDL-kolesterolniveauet.
In the main study Pravafenix was shown to be more effective than pravastatin alone in reducing non- HDL-cholesterol levels.
I hovedundersøgelsen, hvori der deltog 828 patienter med KOL, blev to forskellige doser Bretaris Genuair (200 og 400 mikrogram) indgivet to gange dagligt sammenlignet med placebo (en virkningsløs behandling).
In the main study involving 828 patients with COPD, two different doses of Bretaris Genuair (200 and 400 micrograms) given twice a day were compared with placebo (a dummy treatment).
I hovedundersøgelsen, hvori der deltog 828 patienter med KOL, blev to forskellige doser Eklira Genuair (200 og 400 mikrogram) indgivet to gange dagligt sammenlignet med placebo (en virkningsløs behandling).
In the main study involving 828 patients with COPD, two different doses of Eklira Genuair (200 and 400 micrograms) given twice a day were compared with placebo (a dummy treatment).
I hovedundersøgelserne blev insulin glargin 100 enheder/ml givet en gang dagligt ved sengetid sammenlignet med humant insulin NPH (et middellangt virkende insulin) givet en eller to gange dagligt.
The main studies compared insulin glargine 100 units/ml given once a day at bedtime with human insulin NPH (an intermediate-acting insulin) given once or twice a day.
I hovedundersøgelserne blev NovoNorm sammenlignet med andre lægemidler, som anvendes til type 2-diabetes (glibenclamid, glipizid eller gliclazid).
The main studies compared NovoNorm with other medicines used in type 2 diabetes (glibenclamide, glipizide or gliclazide).
I hovedundersøgelserne blev Prandin sammenlignet med andre lægemidler, som anvendes til type 2- diabetes (glibenclamid, glipizid eller gliclazid).
The main studies compared Prandin with other medicines used in type 2 diabetes (glibenclamide, glipizide or gliclazide).
I HPV-020-studiet, som blev udført i Sydafrika, fik 22 ikke-hiv-inficerede personer og 42 hiv- inficerede personer (WHO klinisk trin 1; ATP-kohorten for immunogenicitet) Cervarix.
In study HPV-020, conducted in South Africa, 22 HIV uninfected and 42 HIV infected subjects (WHO clinical stage 1; ATP cohort for immunogenicity) received Cervarix.
I Humalog BASAL findes insulin lispro uopløst i en væske med protaminsulfat, så det virker i længere tid.
The insulin lispro in Humalog BASAL is available in a suspension together with protamine sulphate, so that its action is prolonged.
I humane in vitro mikrosomale og hepatocyt-studier, resulterer hydrolyse af amidgruppen i den C-terminale aminosyre, phenylalanin, i en deamineret metabolit, og dannelsen af denne metabolit er ikke NADPH-afhængig.
in vitro human microsomal and hepatocyte studies, hydrolysis of the amide group of the C-terminus amino acid, phenylalanine results in a deamidated metabolite and the formation of this metabolite is not NADPH dependent.
I humane levermikrosomer (HLM) synes N-dealkyliseringstrinnet at blive katalyseret af CYP3A4, da safinamid- clearance i HLM blev hæmmet 90 % af ketoconazol.
In human liver microsomes (HLM), the N-dealkylation step appears to be catalysed by CYP3A4, as safinamide clearance in HLM was inhibited by ketoconazole by 90%.
I humane vaskede blodlegemer forekom hæmolyse også med ikke-kommercielle formuleringer af fosaprepitant ved koncentrationer på 2,3 mg/ml og højere, selvom tests af humant blod var negative.
In human washed blood cells also evidence of hemolysis was found with non-commercial formulations at fosaprepitant concentrations of 2.3 mg/ml and higher, although tests in human whole blood were negative.
I humant serum er hovedmetabolitten N-demethyltoremifen med en middel halveringstid på 11 dage (variation 4-20 dage).
In human serum the main metabolite is N-demethyltoremifene with mean half-life of 11 (range 4 - 20) days.
I husstande med influenzasmittede indekstilfælde var der en reduktion i forekomsten af influenza fra 26 % (23/89) i gruppen, der ikke fik forebyggelsesbehandling til 11 % (9/84) i den gruppe, der fik forebyggelsesbehandling (58,5 % reduktion [95 % konfidensinterval 15,6-79,6, p=0,0114]).
In households of influenza-infected index cases, there was a reduction in the incidence of influenza from 26 % (23/89) in the group not receiving prevention to 11 % (9/84) in the group receiving prevention (58.5 % reduction [95 % CI 15.6 – 79.6; p = 0.0114]).
I hver 28-dages cyklus får patienten også lenalidomid og dexamethason til behandling af kræften.
In addition, during each 28-day cycle, the patient also receives cancer treatment with lenalidomide and dexamethasone.
I hver 4-ugers cyklus skal du kun tage en dosis dexamethason den første dag i hver uge.
In every 4-week cycle a dose of dexamethasone should be taken on the first day of each week only.
I hver 4-ugers cyklus skal du tage Imnovid én gang dagligt i 3 uger, efterfulgt af en pause på en uge.
In every 4-week cycle, Imnovid should be taken once a day for 3 weeks, followed by a week off.
I hver 4. uge doseringsstudiet, havde 113 ud af 458 patienter (24,7%) behandlet med 300 mg hver 4. uge/ 150 mg hver 2. uge to på hinanden følgende LDL-C værdier < 25 mg/dL (<0,65 mmol/L), og 45 ud af 458 patienter (9,8%) havde to på hinanden følgende LDL-C værdier < 15 mg/dL (<0,39 mmol/L).
In the every 4 week dosing study, 113 of 458 patients (24.7%) treated with 300 mg every 4 weeks/150 mg every 2 weeks had two consecutive calculated LDL-C values <25 mg/dL (<0.65 mmol/L), and 45 of 458 patients (9.8%) had two consecutive calculated LDL-C values <15 mg/dL (<0.39 mmol/L).
I hver af de kliniske undersøgelser med behandling af VOD var mere end 50 % af patienterne under 18 år.
In each of the clinical studies performed in the treatment of VOD, over 50% of patients were under the age of 18 years.
I hver behandlingsgruppe var der en lidt større procentdel af forsøgspersoner med 2+ linjer af tidligere systemisk behandling mod avanceret sygdom (58 % og 55 % i henholdsvis placebo- og pazopanib- armen) sammenlignet med 0 og 1 linjer af tidligere systemisk behandling (42 % og 45 % i henholdsvis placebo- og pazopanib-armen).
In each treatment group, there was a slightly greater percentage of subjects in the 2+ lines of prior systemic therapy for advanced disease (58 % and 55 % respectively for placebo and pazopanib treatment arms) compared with 0 or 1 lines of prior systemic therapy (42 % and 45 % respectively for placebo and pazopanib treatment arms).
I hver pakning
In each pack